Clinical Trial Update: Clinical Study of BRL-101 in Severe SCD [NA]

View source ↗

Summary

Clinical trial update indicating that BRL-101 is enrolling by invitation for severe sickle cell disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• BRL-101

Snippet

Sponsor: Bioray Laboratories | Conditions: Sickle Cell Disease | NA | Status: ENROLLING_BY_INVITATION